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Abstract 20 
Adenoviruses express up to 20 distinct mRNAs from five major late transcription unit (MLTU) 21 
regions L1-L5 by differential splicing and polyadenylation of the primary transcript. MLTU 22 
expression is regulated at transcriptional and post-transcriptional levels. L4-33K protein acts as a 23 
splicing factor to upregulate several MLTU splice acceptor sites as the late phase progresses. The L4 24 
region also expresses a 22K protein that is sequence-related to L4-33K. L4-22K is shown here also 25 
to have an important role in regulating the pattern of MLTU gene expression. An adenovirus genome 26 
containing a stop codon in the L4-22K ORF expressed low levels of both structural and non-27 
structural late proteins compared to a wt genome; a decrease in intermediate proteins, IVa2 and IX, 28 
was also observed. However, early protein synthesis and replication were unaffected by the absence 29 
of L4-22K. Intermediate and late protein expression was restored to wt levels by L4-22K expressed 30 
in trans but not by L4-33K. Increased MLTU promoter activity, resulting from stabilisation of the 31 
transcriptional activator IVa2 by L4-22K, made a small contribution to this restoration of late gene 32 
expression. However, the principal effect of L4-22K was on the processing of MLTU RNA into 33 
specific cytoplasmic mRNA. L4-22K selectively increased expression of penton mRNA and protein 34 
whereas splicing to create penton mRNA is known not to be increased by L4-33K. These results 35 
indicate that L4-22K plays a key role in the early-late switch in MLTU expression, additional to and 36 
distinct from the role of L4-33K. 37 
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Introduction  38 
 Human adenovirus serotype 5 (Ad5) is considered as a candidate delivery vector for gene 39 
therapy and vaccination. However, despite already achieving use in a clinical setting, some key 40 
questions about the basic biology of Ad5 remain. One of these unsolved questions is how control is 41 
achieved of late protein expression from the major late promoter (MLP), which directs the 42 
production of an array of structural proteins from the major late transcription unit (MLTU) regions 43 
L1 – L5 via differential splicing and polyadenylation of the primary transcript (Fig. 1A, reviewed in 44 
(1)). Understanding late gene expression is important for further Ad vector development since Ad 45 
E1A- vectors that retain late genes show poor persistence of transgene expression due to immune 46 
responses to residual late gene expression products (27, 41-44). 47 
Full expression from the Ad5 MLTU is the end result of a temporal pattern of regulated gene 48 
expression that has several phases (reviewed in (35)). The earliest event is expression of the E1A 49 
transcriptional activator proteins. These then upregulate transcription of the other early viral genes 50 
E1B, E2, E3 and E4. Despite its name, the MLP is active at a low level during this early phase, 51 
producing the abundant i-leader protein and L1-52/55K (38). Accumulation of E2A-DNA binding 52 
protein (DBP) and E2B- precursor terminal protein (pTP) & DNA polymerase (Pol) allows viral 53 
DNA replication to begin. Around the onset of DNA replication, MLTU expression expands to 54 
include L4 proteins (22). The intermediate gene products, IVa2 and IX are also expressed at this time. 55 
IVa2 expression is regulated by a cellular repressor that is titrated out upon genome replication (19). 56 
IX and IVa2 are involved in upregulating transcriptional activity of the MLP during the early to late 57 
phase transition of MLTU expression (25, 26, 32, 40). However, it is only as viral DNA replication 58 
progresses that the MLP is activated to produce maximal expression of the late structural genes from 59 
all of MLTU regions. 60 
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The temporal pattern of MLTU expression involves regulation at both the transcriptional and 61 
post-transcriptional levels. Early in infection, transcription does not proceed beyond the L3 62 
polyadenylation site, and the L1 polyadenylation site is preferentially used leading to the 63 
accumulation of L1-52/55K protein (30). After the initiation of viral DNA replication, MLP activity 64 
increases and transcription extends through L4 and L5 regions, allowing a full complement of 65 
structural proteins to be produced. Alongside these transcriptional changes, RNA processing is 66 
regulated to give altered patterns of mRNA. For example, in the L1 region the proximal 52/55K 67 
splice acceptor site is used almost exclusively at early times but during the late phase usage shifts to 68 
the distal IIIa acceptor site, due to the production of an infection-specific splicing factor (1). This has 69 
now been shown to be L4-33K (39).  70 
L4 is now also known to encode a 22 kDa protein (L4-22K) (31), as predicted from 71 
bioinformatic analysis (11), that shares its N-terminus with L4-33K but has a unique C-terminal 72 
domain (Fig. 1B). L4-22K has a role in genome packaging via its binding, in association with IVa2, 73 
to the A2 sequence within the packaging signal (31, 45, 46).  L4-22K has also been shown to bind, 74 
with IVa2, to the downstream elements (DE1, DE2) of the MLP (31), which have been shown 75 
previously to bind IVa2 as both a homodimer (DEF-B) (25, 40) and in complex (DEF-A) with an 76 
unidentified viral protein (25, 28) suggesting that L4-22K, in conjunction with IVa2, may play a role 77 
in activating the MLP (31). However, DEF-A has also been shown to contain L4-33K, and IVa2 plus 78 
L4-33K activated a MLP reporter (2). Thus it is uncertain what the relative contributions of these 79 
two L4 proteins are to regulation of the MLP. The sequence-relatedness between L4-22K and L4-80 
33K also raises the possibility that they might have overlapping functions. We therefore sought to 81 
analyse the impact of L4-22K on the expression of Ad5 late proteins. Our data show that L4-22K is 82 
required for the transition to late phase MLTU expression and acts primarily at the level of RNA 83 
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processing. However, the action of L4-22K is different from that of the splice factor L4-33K and the 84 
two proteins are not functionally redundant. 85 
 86 
Materials and Methods 87 
Plasmids. pTG3602 (pWT), containing wild type Ad5 genome, and pTG3602-L4-22K- (pL4-22K-), 88 
containing a premature stop codon within the C-terminal unique portion of the L4-22K ORF that 89 
results in an additional AvrII restriction recognition site (Fig. 1B), have been described previously (8, 90 
31). Expression plasmids for C-terminal FLAG-tagged L4-22K and L4-33K (pCMV-22KFLAG and 91 
pCMV-33KFLAG) were constructed by insertion of XbaI/PacI fragments, amplified respectively 92 
from viral genomic DNA or viral mRNA using primers containing the restriction enzyme recognition 93 
sites (primer sequences available on request), into pCMV-FLAG (12). pBiL1-3NheI, pCMV-94 
100KFLAG, and pCMV-22/33KFLAG, which expresses both L4-22K (no epitope tag) and L4-95 
33KFLAG (12), pCMV-IX (5) and pMEPCMV-IVa2 (4) have been described previously. 96 
pMLP+DEluc was generated by amplifying the MLP including DE1 and DE2 (Ad5 5939-6174) 97 
using primers containing restriction recognition sites for KpnI (5’ primer) and NheI (3’ primer) and 98 
cloning into pGL3-Basic luciferase reporter plasmid (Promega). pMLP-DEluc, containing the MLP 99 
without the downstream elements (Ad5 5939-6133), was generated in a similar way. 100 
pcDNA3.1HisLacZ (Invitrogen) was used as a transfection control. 101 
 102 
Cells and Viruses. 293 cells were maintained in Dulbecco’s MEM (DMEM) supplemented with 5% 103 
fetal bovine serum (FBS). 293-IVa2 cells constitutively express IVa2 from an EBV replicon plasmid 104 
(4). 293TetOFF cells (Clontech) were maintained in DMEM supplemented with 10% Tet-free FBS 105 
and 100µg/ml geneticin (G418 sulphate, Melford Laboratories). An L4-22K complementing, stable 106 
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cell line (293-L4-22K) was generated by transfecting 293 cells with pCMV-22KFLAG and selecting 107 
clones in DMEM supplemented with 10% FBS and 500µg/ml geneticin. L4-22KFLAG expression 108 
was confirmed by immunoblotting and immunofluorescence using a mouse mAb to FLAG (M2, 109 
Sigma). 110 
Wild-type virus was Ad5 strain 300 (wt300) (21). To generate an L4-22K- virus, 293-L4-22K 111 
cells were seeded into a 12 well plate and transfected with L4-22K- genome, excised from pTG3602-112 
L4-22K- by PacI digestion, using Lipofectamine2000 (Invitrogen). When 60-80% cpe was observed 113 
cells were harvested, virus released by three freeze/thaw cycles and cellular debris removed by 114 
centrifugation. This L4-22K- virus stock was passaged 5 times to ensure removal of transfected 115 
genomic DNA. To confirm the presence of the mutated sequence in the P5 stock, virus particle DNA 116 
was isolated (16) and used as template for a PCR to amplify the Ad5 L4 region 26018-27086bp. PCR 117 
products were then digested with AvrII, which is diagnostic for the 22K- mutant (31). Virus titres 118 
were determined by fluorescent focus assay. Briefly, 293 cells were infected with a 10-fold dilution 119 
series of L4-22K- virus or wt300, fixed at 20h.p.i. with 10% formalin in phosphate-buffered saline 120 
(PBS) and permeablized with 0.5% NP40 in PBS before staining with a mouse mAb to DBP (B6-8, 121 
(34)) and goat anti-mouse Alexafluor488 antibody (Invitrogen). Virus titres (FFU/ml) were 122 
determined by the number of DBP positive cells at a given dilution (33). For wt300, 1 FFU was 123 
equivalent to 7 pfu. 124 
 125 
Transfection and Immunoblotting. All transient transfections were carried out in 12 well plates at 126 
a density of 7x105 cells/well using either Lipofectamine2000 (Invitrogen) or TransLT (Cambridge 127 
Bioscience) at a ratio of 3µl /  µg DNA following the manufacturers’ protocols. Transfections used 128 
1µg L4-22K- or wt genome, excised from pL4-22K- or pWT respectively by PacI digestion, and 129 
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500ng various expression plasmids or empty vector (pCMV-FLAG). Experiments using the pBi 130 
plasmid system were carried out as previously described (12). Transfected cells were harvested 48h 131 
post-transfection directly into sample loading buffer (2% (w/v) sodium dodecyl sulphate [SDS],  132 
50mM dithiothreitol [DTT], 10 % (v/v) glycerol, 25mM Tris pH 6.8 and 0.01 % bromophenol blue) 133 
and from 10 - 33% cell lysate volume resolved through either 10% or 15% SDS-polyacrylamide gels 134 
as appropriate. Proteins were transferred to ECL nitrocellulose membrane (GE Healthcare) and 135 
western blot analysis carried out as described (23).  Proteins were detected using the following 136 
antibodies: FLAG,  M2 mouse mAb (Sigma) at 1:10,000; Ad5 late proteins, AbJLB1 rabbit 137 
polyclonal serum at 1:10,000 (12); fibre, RI 89&99  rabbit polyclonal serum 1:5000 (obtained from 138 
V. Mautner, University of Birmingham, U. K.); E2A-DBP, mouse mAb B6-8 at 1:10,000; L1-139 
52/55K, rabbit polyclonal serum raised to glutathione-S-transferase (GST) - L1-52/55K fusion 140 
protein at 1: 10,000, (3); L4-100K, mouse mAb at 1:10,000 (obtained from W.C. Russell, University 141 
of St. Andrews, (36)); IVa2, rabbit polyclonal serum raised to GST-IVa2 at 1:10,000, (4); IX, rabbit 142 
polyclonal serum at 1:5000, (5). Secondary antibodies were goat-anti-mouse-horseradish peroxidise 143 
(HRP; Sigma) at 1:5000 and goat-anti-rabbit-HRP (Santa Cruz) at 1:100,000. HRP signal was 144 
detected using ECL-Advance western blot detection kit (GE Healthcare) according to the 145 
manufacturer’s instructions. 146 
 147 
RT-PCR. Cells were scraped into PBS, pelleted by centrifugation, resuspended in isotonic buffer 148 
(150 mM NaCl, 10 mM Tris.HCl pH 7.6, 1.5 mM MgCl2) containing 0.6% v/v NP40 and incubated 149 
on ice for 10 min. before pelleting the nuclei by centrifugation at 16000 x g for 3 min. The 150 
cytoplasmic fraction was reserved and the nuclei resuspended in lysis solution (isotonic buffer 151 
containing 1% NP40 and 1% sodium deoxycholate). RNA was isolated from both the nuclear and 152 
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cytoplasmic fraction using TRI-reagent (Sigma) as described (29). 2µg RNA and 100U Superscript 153 
reverse transcriptase (RT; Invitrogen) were used with specific 3’ primers to generate cDNA in a 25µl 154 
volume reaction using manufacturer’s protocol.  Equivalent RT- negative reactions omitted 155 
Superscript. 2.5µl RT+ or RT- reaction were added to a PCR (1x PCR buffer, 0.5mM each dNTP, 156 
0.5µM 5’ and 3’ primer, 3mM MgCl2 and 1-2.5U Taq polymerase (Fermentas) in a total volume of 157 
20µl). Primers used were complementary to Ad5 tripartite leader 1 sequence 6049-6069 and Ad5 L2-158 
penton 14889-14863, Ad5 L2-V 17445-17415 or Ad5 L3-hexon 19254-19228, or to sequences 159 
flanking the Ad5 L3 poly(A) and E2A poly(A) sites 22034-22061 and 22749-22722, or to human β-160 
actin cDNA positions 1430-1455 and 2383-2368. Reactions were incubated at 94°C for 5 min 161 
followed by 30 cycles of 94°C, 1 min, 65°C, 1 min and 72°C, 1 min. PCR products were resolved 162 
through 1% agarose alongside size markers (1kb Generuler, Fermentas). 163 
 164 
Southern Blot Analysis. 293 cells were infected with 2 x 10-3 FFU/cell L4-22K- virus or wt300, and 165 
harvested 3 or 20h. p.i. Cells were processed either to purify packaged viral DNA, using spermine 166 
precipitation to remove unpackaged material (16), or for total low molecular weight DNA by HIRT 167 
extraction (18). DNA was digested with HindIII, resolved through 0.7% agarose and transferred to 168 
Hybond-N membrane (GE Healthcare) and viral DNA detected using an L1 probe (10,589-11,565bp 169 
from pGem4-L1 (37)) labelled using the AlkPhos direct labelling kit (GE Healthcare).  170 
 171 
Luciferase Assay. 293 and 293-IVa2 cells were transfected with 500ng reporter plasmid 172 
(pMLP+DEluc or pMLP-DEluc) and 100ng pcDNA3.1HisLacZ, together with 500ng pCMV-173 
22KFLAG and/or 1µg L4-22K- genome. All transfections were equalised for DNA content by the 174 
addition of either salmon sperm DNA or pCMV-FLAG as appropriate. Cells were lysed 24h post-175 
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transfection in 1x passive lysis buffer and a luciferase assay carried out according to the 176 
manufacturer’s instructions (Promega). Cell lysates were also analysed for β-galactosidase activity 177 
using 2-nitrophenyl-β-D-galactopyranoside (ONPG) as substrate. The ratio of firefly luciferase to β-178 
galactosidase was calculated to correct for differences in transfection efficiency. Data are shown as 179 
fold induction where luciferase expression from the reporter plasmids is set as 1. Statistical analysis 180 
was performed using Student’s T-Test. 181 
 182 
Results 183 
L4-22K is required for efficient late gene expression in 293 cells. Our previous studies of the 184 
early to late transition in MLTU expression utilised plasmid pBiL1-3NheI, in which MLTU genomic 185 
sequence encoding the tripartite leader (TPL) and regions L1 – L3 was placed under the control of a 186 
heterologous promoter. Full late pattern expression could be induced from this plasmid by CMV 187 
expression vectors encoding L4-33K and -100K proteins (12). The “33K” plasmid utilised was also 188 
capable of L4-22K expression, although L4-22K had not been proven to exist at that time. 189 
Subsequently, L4-33K was shown by Tormanen et al. to be a splicing factor capable of activating 190 
certain MLTU splice sites (39). To determine whether L4-22K made any contribution to the MLTU 191 
activation observed in this system, plasmids expressing either L4-22K or L4-33K with C-terminal 192 
FLAG tags were constructed. When co-transfected with pBiL1-3NheI and an L4-100K vector to 193 
permit efficient hexon protein accumulation, L4-22KFLAG increased levels of several late proteins 194 
independently of L4-33K (Fig. 1C). These effects were qualitatively distinct, with L4-22K increasing 195 
penton expression more than, and hexon expression less than did L4-33K. These data suggested that 196 
L4-22K made a contribution to late protein expression from L1-L3, although it could not be excluded 197 
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that this effect was due to expression of a truncated L4-33K-related protein from the L4-22K plasmid 198 
clone. 199 
To investigate fully the role of L4-22K in regulating MLTU expression, given the prior 200 
evidence that L4-22K and/or L4-33K might act on the MLP, we focused further studies on a whole 201 
genome system, in which the MLTU was controlled by the native MLP within linear full-length 202 
genome excised from pTG3602 (8). This also provided the possibility of IVa2 production that was 203 
not present in the pBi plasmid system. The role and mechanism of action of L4-22K in late gene 204 
expression from this genome was assessed by comparison with an L4-22K- genome that retained the 205 
ability to express full-length L4-33K (Fig. 1B, (31)), kindly provided by P. Hearing. 206 
293 cells transfected with L4-22K- genome showed a decrease in late structural protein 207 
production (hexon, penton, IIIa, V and fibre) compared to a wt genome (Fig. 2A & B); while the 208 
absolute level of this defect varied between experiments, as exemplified here, it was always 209 
substantial. In addition, expression of the non-structural late proteins L4-100K and L1-52/55K from 210 
L4-22K- genome was reduced to virtually undetectable levels (Fig. 2B). The level of E2A-DBP 211 
detected was at least equivalent for L4-22K- and the wt genome, and possibly somewhat increased in 212 
the mutant, demonstrating that the defect in late protein expression was not due to differences in 213 
transfection efficiency and that the absence of L4-22K does not cause a global downregulation of 214 
viral protein production. Expression of all late proteins from the L4-22K- genome was restored to 215 
wild-type levels when cells were co-transfected with an expression plasmid for L4-22KFLAG (Fig. 216 
2A), confirming that the reduced late protein expression seen from L4-22K- genome was due solely 217 
to the lack of L4-22K expression. L4-22K has been shown previously to be involved in the 218 
packaging of Ad genomes into particles (31), so at 48 h post-transfection it was possible that the 219 
observed differences in late gene expression resulted from reduced levels of second-round infection 220 
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in L4-22K- genome-transfected cultures consequent upon a failure to package genomes efficiently. 221 
However, this possibility was discounted as similar results were observed at 20 h post-transfection, a 222 
time point when no progeny virus would have been able to reach the late phase of a secondary 223 
infection (data not shown). The late protein defect of L4-22K- is kinetic rather than absolute as, when 224 
analysis was delayed to 60 h post-transfection, L4-22K- genome produced similar levels of late 225 
proteins to those seen at 20 h post-transfection for either wt genome or L4-22K- genome co-226 
transfected with L4-22KFLAG expression plasmid (data not shown). Thus L4-22K upregulates late 227 
gene expression in 293 cells.  228 
 229 
L4-22K acts via a different mechanism to L4-33K.  The stop codon inserted into the L4-22K ORF 230 
in pL4-22K- is located within the intron sequence of L4-33K ORF and it was possible that this 231 
mutation might affect the expression of L4-33K, hence causing some part of the observed defect in 232 
late protein production. Although the defect was complemented by L4-22KFLAG, this plasmid also 233 
has the capacity to express a truncated L4-33K protein consisting of the N-terminal 129 amino acids 234 
that might contribute to this complementation. The truncated protein would lack the C-terminal RS 235 
motifs that have been show to be essential for this activity (39), making this unlikely. However, to 236 
exclude the possibility, L4-22K- was co-transfected with an expression plasmid for L4-33KFLAG. 237 
Expressing L4-33KFLAG in trans did not restore expression of either the structural proteins or L4-238 
100K (Fig. 2B), although a small increase in L1-52/55K was observed. Late protein expression from 239 
L1 through to L5 was only restored when L4-22K was added in trans either from pCMV-22KFLAG 240 
or from a plasmid, pCMV-22/33KFLAG, capable of expressing both L4-22K and L4-33KFLAG 241 
from alternatively spliced transcripts (Fig. 2B). During complementation by pCMV-22K/33KFLAG, 242 
expression of the structural proteins and L4-100K was greater than that seen with L4-22K- genome 243 
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alone but was reduced compared to when L4-22KFLAG was expressed from pCMV-22KFLAG. 244 
This may reflect preferential expression of the spliced L4-33KFLAG transcript from this plasmid 245 
and consequently a lower expression level of L4-22K protein than was achieved with pCMV-246 
22KFLAG. These data show that the defect in late gene expression is not due to any unexpected 247 
aberrations in L4-33K expression occurring due to the mutation in the intronic sequence of L4-33K 248 
ORF. Furthermore, the evidence clearly shows the mechanism of action of L4-22K is independent of 249 
L4-33K splicing function and thus indicates a direct role for L4-22K in the activation of the late 250 
phase of infection. 251 
 252 
Reduced late gene expression in the absence of L4-22K is not due to a defect in replication. Full 253 
expression from the Ad5 MLTU is the end result of a temporal pattern of regulated gene expression. 254 
It is only once viral DNA replication has begun that the MLP is activated to produce maximal 255 
expression of the late structural genes from all MLTU regions. Thus a defect in replication could 256 
account for the reduction in late protein production observed from L4-22K- genome. To allow 257 
replication studies to be carried out without the concern of transfection efficiencies or the confusion 258 
of large quantities of input DNA, L4-22K- virus was isolated by transfection of L4-22K- genome into 259 
a stable L4-22K complementing cell line, 293-L4-22K. Although this cell line only expressed a low 260 
level of L4-22KFLAG, it was sufficient to permit the growth of virus to low titre. 261 
The production of L4-22K- virus was confirmed by AvrII digest of PCR products amplified 262 
from DNA isolated from L4-22K- virus particles (Fig. 3A). Using particle DNA ensured that only 263 
newly synthesised and packaged DNA was acting as a template in the PCR and not any remaining 264 
transfected genome. Incubation of the L4-22K- virus product with AvrII resulted in the virtually 265 
complete cleavage to bands 532 and 536bp in size, indicating presence of the site diagnostic of the 266 
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L4-22K- mutation (31). The small amount of uncut DNA is likely to represent incomplete digestion. 267 
If any wild-type DNA was present, it would rapidly overgrow the slow-growing mutant but no 268 
increase in the proportion of this uncut species was seen upon further passage; the presence of the 269 
inserted stop codon was also confirmed by sequencing (data not shown). The L4-22K- virus had the 270 
packaging defect expected from previous work (Fig. 3B) (31). At 20 h. p.i. viral DNA was not 271 
detected for L4-22K- unless complemented by prior expression of L4-22KFLAG; when 272 
complemented, amounts of L4-22K- DNA were similar to wt virus. No viral DNA was detected at 3 273 
h. p.i. indicating that viral DNA detected at 20 h. p.i. was due to newly synthesised, packaged 274 
genomic DNA and not virus input. These data confirm the L4-22K deficient nature of the L4-22K- 275 
virus generated in this study both genetically and biologically.  276 
To investigate the growth properties of L4-22K-, the late protein expression defect observed 277 
with transfected genome was first confirmed. Non-complementing cells infected with L4-22K- virus 278 
behaved identically to cells transfected with L4-22K- genome in showing a substantial impairment of 279 
structural protein expression (data not shown). Genome replication was then assessed (Fig. 3C). At 280 
3h. p.i. a low level of viral DNA was detected; this time point is too early for the synthesis of 281 
progeny viral DNA and thus shows the amount of input viral DNA. The increased level of viral DNA 282 
detected at 20 h. p.i. was similar for uncomplemented and complemented L4-22K- virus,  showing 283 
that the absence of L4-22K has no effect on virus DNA replication. This result agrees with that 284 
reported previously in which replication of the L4-22K- genome was investigated in HeLa cells (31). 285 
The block in MLTU gene expression must therefore occur after DNA replication. 286 
 287 
A reduction in intermediate proteins IVa2 and IX is not fully responsible for the reduction in 288 
late protein expression from L4-22K-. The two intermediate proteins, IVa2 and IX upregulate the 289 
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MLP activity during the transition between the early and late phases of infection (25, 26, 32, 40). 290 
IVa2 acts via binding, either as a homodimer (DEF-B) or heterodimer (DEF-A), to sequences DE1 291 
and DE2 within the MLP (20, 28). Furthermore, the pattern of differential protein expression 292 
observed here in the absence of L4-22K is similar to that reported previously for MLP DE1 and DE2 293 
mutants (32) suggesting that L4-22K may be acting via IVa2, perhaps as a component of DEF-A 294 
since enhanced binding of IVa2 to DE1,2 in the presence of 22K has been reported (31).  295 
Expression of IVa2 and IX from L4-22K- genome alone was barely detectable, whereas 296 
levels of both proteins were substantially increased when L4-22KFLAG was co-expressed (Fig. 4A). 297 
To determine whether this reduction in intermediate proteins was responsible for the limited 298 
expression of late proteins observed for L4-22K- genome, these two proteins were expressed in trans. 299 
Co-transfection of L4-22K- genome with IVa2 expression plasmid increased expression of hexon, 300 
penton and the smaller isoform of protein V, but failed to increase IIIa, the upper isoform of V or 301 
pVI (Fig. 4B). In contrast, co-transfection with IX expression plasmid failed to increase the level of 302 
late gene expression significantly. When IX and IVa2 were expressed together, the level of all late 303 
proteins tested increased a little as compared to either protein alone. However, this late protein 304 
expression was very much lower than that seen when the L4-22K- genome was directly 305 
complemented by L4-22KFLAG (Fig. 4B). 306 
L4-22K clearly increases the level of both IVa2 and IX proteins produced from transfected 307 
genome (Fig. 4A). In the case of IVa2 this may reflect a stabilisation of the protein rather than a 308 
transcription or RNA processing event since L4-22KFLAG also increases the level of IVa2 protein 309 
expressed from cDNA under the control of the heterologous CMV promoter (Fig. 4C); this effect 310 
was specific to L4-22K as neither L4-33KFLAG nor L4-100KFLAG had any effect (Fig. 4C). This 311 
observation suggests that the increase in IVa2 seen when L4-22K- genome is complemented is not 312 
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mediated through IVa2’s interaction with L1-52/55K, its known partner in viral DNA packaging (15), 313 
expression of which also increases upon complementation of L4-22K- (Fig. 2B). The IVa2 sequence 314 
within pMEPCMV-IVa2 does not contain the binding site for the cellular repressor that blocks IVa2 315 
transcription prior to replication (9, 24) and thus L4-22K cannot be acting by relieving this 316 
repression. In addition, no effect of L4-22K on expression of other proteins from the CMV promoter 317 
was observed (data not shown). Therefore, we hypothesise that L4-22K acts to stabilise IVa2 protein.  318 
It is possible that lack of IVa2 stabilisation by L4-22K is the reason why IVa2 expressed in 319 
trans can only partially complement the late protein expression defect of L4-22K- genome. However, 320 
this seems unlikely as the levels of IVa2 achieved were similar to those seen when L4-22K- was fully 321 
complemented by L4-22KFLAG. Furthermore, similar results were obtained when a cell line 322 
constitutively expressing high levels of IVa2 was used (Fig. 5C), excluding the possibility that L4-323 
22K somehow affects IVa2 transfection efficiency. Alternatively, the requirement for L4-22K may 324 
reflect a direct contribution of this protein to the DEF-A transcription factor that is required for 325 
maximal activation of the MLP (31). 326 
 327 
L4-22K increases MLP activity in a DE-dependent manner. To determine if L4-22K directly 328 
regulated transcription from the MLP, and whether this was DE-dependent, luciferase expression 329 
from MLP reporters either containing or lacking DE1,2 was assessed in the presence of the L4-22K- 330 
genome or complemented genome (Fig. 5A). The presence of the genome ensured all viral proteins, 331 
other than L4-22K, that might be required for transcriptional activation were present in the system. 332 
Luciferase expression was increased 45-60 fold by the presence of the L4-22K- genome, regardless 333 
of the presence or absence of the DE elements. This significant increase occurred despite the fact that 334 
the L4-22K- genome displays a severe reduction in IVa2, IX and late protein synthesis. Expression of 335 
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L4-22KFLAG further increased the activity of pMLP+DEluc by two-fold compared to L4-22K- 336 
genome alone (p<0.005), whereas the activity of pMLP-DEluc was not significantly altered (p>0.1), 337 
demonstrating that the increase was DE-dependent (Fig. 5A). In contrast, L4-22KFLAG expressed in 338 
the absence of viral genome had no effect on the activity of MLP containing the DEs (Fig. 5B), 339 
suggesting that another viral protein was required in association with L4-22K.  340 
 A likely candidate protein was IVa2, which was known to act via the DEs (40) and had been 341 
shown to be stabilised in the presence of L4-22K (Fig. 4). To test whether DE-dependent MLP 342 
activation by L4-22K was indirectly due to increased IVa2 levels or due to a direct interaction of L4-343 
22K and IVa2 at the DEs, MLP reporter activity was analysed in a cell line constitutively expressing 344 
high levels of IVa2 (293-IVa2) (4). Activity of the DE-containing MLP in 293-IVa2 cells was 345 
increased a modest 1.2 fold compared to its activity in 293 cells. When L4-22KFLAG was co-346 
expressed in these cells, the increase was 1.6 fold compared to 293 cells, a 1.3 fold increase 347 
compared to 293-IVa2 cells (Fig. 5B). Therefore, both L4-22K and IVa2 contribute to MLP 348 
activation. However, the small increase in MLP activity observed when L4-22KFLAG is expressed 349 
in the presence of high levels of IVa2 does not explain the large differences in the expression of late 350 
proteins, notably penton and IIIa, from complemented genome in the same cell line (Fig. 5C). This 351 
suggests that L4-22K may have a role in late gene expression that is post-transcriptional, in addition 352 
to its effects, with or via IVa2, at the MLP. This conclusion is supported by the observed increase in 353 
L1-3 gene expression from a heterologous promoter in the presence of L4-22KFLAG, when no IVa2 354 
was present (Fig. 1C). 355 
 356 
L4-22K acts at the level of late gene mRNA production/stability. To determine whether L4-22K 357 
was exerting its post-transcriptional effect at the level of mRNA or protein production, the amounts 358 
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of penton, V and hexon mRNA produced by L4-22K- and wt virus were assessed. Penton and V 359 
mRNA production from L4-22K- virus was barely detectable, compared to readily detectable 360 
expression from wt virus (Fig. 6); this defect was fully complemented when L4-22KFLAG was 361 
expressed in trans (Fig. 6). In contrast, the level of hexon mRNA produced by L4-22K- virus was 362 
similar to that from wt and not further increased when complemented by L4-22K. PCR products 363 
were not from DNA contamination of the template as equivalent reactions containing no reverse 364 
transcriptase were negative (Fig. 6). The quantity and quality of RNA used was confirmed by the 365 
equivalent amplification of β-actin mRNA (Fig. 6). Therefore, a major component of the reduction in 366 
late gene expression observed for L4-22K- is at the level of late mRNA production and/or stability, 367 
and the action of L4-22K is selective for specific mRNAs. 368 
 369 
L4-22K does not increase the level of un-processed late mRNA. To further clarify the role of L4-370 
22K in transcription and RNA processing, the level of unspliced nuclear MLTU RNA was 371 
determined by RT-PCR amplification of a region spanning the L3 polyadenylation signal sequence 372 
(Ad5 22034-22722); this region is only present in RNA unprocessed at the L3 polyadenylation site. 373 
Amounts of unprocessed L3 RNA in wt and L4-22K- virus infections were comparable, and 374 
complementation of L4-22K- virus with L4-22KFLAG had no effect (Fig. 7 left upper panel). The 375 
level of unprocessed E2A RNA, tested as a control since its protein product was unaffected by L4-376 
22K, was equal for all samples as expected (Fig. 7 right upper panel) and control reactions lacking 377 
reverse transcriptase were negative (Fig 7 right lower panel), indicating that the PCR products were 378 
generated from RNA template. These data provide further evidence against a major role for L4-22K 379 
in transcriptional activation of the MLP, and focus attention instead on MLTU mRNA processing as 380 
its principal site of action. 381 
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 382 
Discussion  383 
Ad5 late protein synthesis is regulated at the level of transcription, mRNA processing and 384 
translation. Early in infection, MLTU expression is limited to L1-52/55K. However, after DNA 385 
replication begins, expression extends across MLTU regions L1 through to L5 resulting in over 20 386 
distinct mRNAs and thus proteins. The L4 region is expressed immediately after DNA replication 387 
(22) and two of its three non-structural protein products have been described as factors involved in 388 
the regulation of late protein synthesis. L4-33K is required for late mRNA splicing (12, 39) whereas 389 
L4-100K is responsible for selective translation of late mRNAs (17) and for the stabilisation and 390 
assembly of hexon trimers (6). The results presented here demonstrate that the third L4 non-391 
structural protein, L4-22K, is also involved in the regulation of late protein expression and appears to 392 
have distinct functions in transcription and RNA processing. 393 
A L4-22K deficient genome exhibited a reduction in both structural and non-structural late 394 
protein expression from MLTU regions L1 through to L5 (fibre, hexon, penton, IIIa, V, VI, L4-100K 395 
and L1-52/55K) compared to a wt genome, and this defect was fully complemented by exogenous 396 
L4-22K expression. The first impact of L4-22K deficiency was in the late phase as early gene 397 
expression, demonstrated by E2A-DBP levels, was not affected and newly synthesised DNA levels 398 
from L4-22K- virus-infected cells were comparable to those when L4-22K- was complemented with 399 
exogenous L4-22K. L4-22K has been shown previously to be required for viral genome packaging 400 
(31), and this same defect was also observed in this study. However, failure to package genome 401 
efficiently could not be the cause of the observed reduced late gene expression since the defect was 402 
seen at times post-infection when any secondary infections could not have reached the late phase of 403 
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gene expression. Thus, defective late gene expression is a primary consequence of L4-22K 404 
deficiency.  405 
L4-33K has been shown previously to upregulate late gene expression post-transcriptionally 406 
(12, 39), so it was possible that lack of L4-22K affected late protein production via a failure to 407 
express L4-33K correctly. No antibodies specific for L4-33K were available to test this directly. 408 
However, L4-33K expressed in trans, in constrast to L4-22K, had almost no impact on the defective 409 
late gene expression from L4-22K- genome. Therefore the reduction in late gene expression from this 410 
mutant genome is a direct effect of the absence of L4-22K and a not a consequence of either 411 
unanticipated aberrant expression of L4-33K due to the L4-22K- mutation that lies within the L4-33K 412 
intron or reduction in L4-33K levels that might result from the lack of L4-22K effects on the MLP. 413 
Moreover, the action of L4-22K must be independent of the demonstrated effect of L4-33K on late 414 
mRNA splicing. 415 
When high level transcription from L1-L3 regions was rendered independent of Ad5 IVa2 416 
and other viral factors by the use of a heterologous promoter, complementation by L4-22K 417 
upregulated penton levels disproportionately to hexon, the reverse of the effect of L4-33K. These 418 
observations fit with the work of Tormanen et al. who, when showing that L4-33K was the 419 
previously demonstrated Ad late splicing factor (39), found that L4-33K had no effect on penton 420 
mRNA splicing in vitro. These authors classified splice sites by length of polypyrimidine tract and 421 
showed that splicing stimulation by L4-33K correlated inversely with tract length. Our findings 422 
therefore raise the possibility that L4-22K might also be selective for a particular class of splice site. 423 
If so, it does not correspond to polypyrimidine tract strength; penton and V mRNA levels were both 424 
strongly L4-22K – responsive in our study even though their 3’ splice sites have very different 425 
polypyrimidine tracts and V mRNA splicing was reported to be strongly stimulated by L4-33K in 426 
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contrast to the lack of effect on penton (39). Hexon mRNA accumulation did not require L4-22K in 427 
our study despite hexon protein production being strongly dependent on L4-22K. This discordance is 428 
explained by the dependence of hexon protein accumulation on the presence of L4-100K (12), which 429 
was itself found to be strongly dependent on L4-22K for its expression. Taken together, these data 430 
suggest that L4-33K and L4-22K each act post-transcriptionally to support the development of the 431 
full pattern of late viral gene expression in different ways. 432 
As well as the late proteins, the two intermediate proteins, IVa2 and IX were reduced in the 433 
absence of L4-22K. These two proteins are only expressed after viral DNA replication has begun (10, 434 
19), and both have been implicated in activation of the MLP. The data presented here show that L4-435 
22K increases IVa2 protein levels, independent of the IVa2 promoter and known regulatory 436 
sequences. IVa2 has been shown previously to bind to L4-22K during Ad DNA packaging, and L4-437 
22K also promotes the binding of IVa2 to the MLP DEs (31). Thus, we suggest that L4-22K 438 
increases IVa2 levels by binding and stabilising it, and via this action L4-22K achieves a modest 439 
activation of the MLP that is dependent on the DEs. However, this effect is minor in comparison 440 
with the overall effect of L4-22K on late gene expression.  441 
Previous studies have sought to address the function of L4 proteins through directed mutation 442 
of the L4 reading frames. A virus with a stop codon at position 20 of the shared L4-33K/22K reading 443 
frame (v33K.1) and expected to lack both proteins was viable, with normal early gene expression 444 
and viral DNA replication but a substantial defect in late protein synthesis (13), a phenotype that is 445 
similar to that found here for L4-22K-. However, a virus with its L4-33K reading frame truncated by 446 
stop codons and expected to lack the C-terminal 47 residues proved impossible to isolate, suggesting 447 
it was a lethal mutation (14). This finding suggests that v33K.1 must be leaky for functional L4-33K 448 
expression and hence also for L4-22K, although since we have not been able to complement the ∆47 449 
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mutant genome (kindly provided by S. J. Flint) in a cell line expressing L4-33K (data not shown), it 450 
is also possible that the severe ∆47 phenotype includes pleiotropic effects not directly attributable to 451 
a lack of L4-33K. In this case, v33K.1 may represent the true null phenotype for both L4-22K and 452 
L4-33K. The L4-22K- virus that was isolated here, using the mutated plasmid genome constructed by 453 
Ostapchuk and colleagues (31), was clearly viable and showed defects in late gene expression and 454 
genome packaging. It retained the restriction site difference diagnostic of the original mutation and 455 
its phenotype was identical to that of the transfected genome from which it was derived. Thus, 456 
although it cannot be excluded that its viability results from second-site mutation(s) that compensate 457 
for aspects of the L4-22K- phenotype, this seems unlikely. Because of the shared L4-33K/22K exon, 458 
the L4-22K- mutation truncates the reading frame only after 113 residues. It thus has the potential to 459 
express a substantive protein, albeit containing only 8 residues of the 22K-unique sequence, which 460 
might have residual functions distinct from those of L4-33K. Although no shorter protein 461 
immunoreactive with anti-33K serum was detected from this genome (31), a contribution of such a 462 
protein to the viability of L4-22K- virus cannot be excluded. However, our data, taken together with 463 
previous studies, suggest that Ad5 can grow, albeit with low efficiency, without L4-22K and that 464 
impaired late gene expression and particle formation is the null phenotype for this protein. 465 
Our results on late gene expression in the absence of L4-22K differ from those previously 466 
reported using the L4-22K- genome. Ostapchuk and colleagues reported no differences from wt in 467 
replication, DBP, L1-52/55K, hexon or penton protein levels (31). In this study we also detected no 468 
differences in replication or DBP levels, but detected a clear reduction in the levels of L1-52/55K, 469 
penton and to a lesser extent hexon. We believe the previous data do in fact show some differences 470 
in L1-52/55K and penton levels but to a considerably lesser degree than our data indicate. Different 471 
cell types, 293 and HeLa, were used for the two studies but this does not appear to explain this 472 
   
 Page 22 of 32   
difference since we consistently observed the same L4-22K- late gene expression defect in infected 473 
HeLa cells as seen in 293 cells by either genome transfection or virus infection (data not shown). 474 
Possibly, either culture conditions or HeLa cell strain differences affect the expression of host cell 475 
factors with which L4-22K needs to interact to upregulate late gene expression and hence modulate 476 
the severity of the phenotype observed. Alternatively, differences between the two studies in the 477 
effective time post-infection / transfection that assays were conducted may provide an explanation, 478 
since the defect in late gene expression that we observed diminished as the time to assay was 479 
extended. 480 
 The MLP is activated by several factors, including the binding of DEF-A and DEF-B to the 481 
downstream elements DE1 and DE2. The importance of these factors is most apparent in the absence 482 
of activation via upstream promoter elements (32). DEF-A is a heterodimer of IVa2 and another 483 
protein, and there is published evidence for this protein being either L4-33K or L4-22K (2, 31). Our 484 
data do not bear directly on this issue, since no studies of protein interactions with the DEs were 485 
performed. However, MLP activity was shown to be only modestly stimulated by L4-22K, in 486 
cooperation with IVa2, suggesting that L4-22K is not the unknown component of DEF-A. This does 487 
not exclude that a complex of IVa2 and L4-22K can bind to the DEs, as previously reported (31); 488 
indeed, our data on IVa2 stabilisation suggest that increased IVa2 complex formation on the DEs 489 
when L4-22K is present should be expected.  490 
 In contrast to the modest effects on MLP of IVa2 and L4-22K, the presence of the full viral 491 
genome in trans with the MLP reporter caused a 60-fold increase in activity. This suggests that 492 
something other than IVa2 or L4-22K is required, either another factor expressed from the genome 493 
or the presence of replicating genome itself. One possible factor is E2A-DBP, which has previously 494 
been shown to increase MLP activity substantially (7) and is expressed from L4-22K-. Another 495 
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potential activating factor coming from L4-22K- is E1A. However,  293 cells already express E1A, 496 
and we have observed only a slight increase in luciferase expression from another E1A-responsive 497 
reporter in these cells when E1A is further over-expressed, Nonetheless, it is possible that the 498 
population of E1A isoforms expressed in 293 cells is functionally altered during viral infection and 499 
that the activation of the MLP in this context is a reflection of this. Further experiments are therefore 500 
required to determine the basis of MLP activation by Ad genome. 501 
This study, together with previous reports, shows that the L4 region of the MLTU provides 502 
two crucial regulators of the temporal transitions in MLTU RNA processing that are observed over 503 
the course of Ad infection. L4-22K and L4-33K have complementary effects that together provide 504 
the normal pattern of mRNA production during the late phase of infection. L4-33K was shown 505 
previously to be a splicing factor that activates splicing to specific late mRNA 3’ splice sites. 506 
However, this activity did not extend to all splice sites whose activity is seen to increase during the 507 
early-late transition in MLTU expression. It is possible that L4-22K is also a splicing factor, but with 508 
a distinct specificity from L4-33K. Alternatively, it may act less directly, perhaps via changes in host 509 
proteins. Further experiments are needed to address these questions. 510 
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 633 
Figure legends 634 
Figure 1. (A) Schematic diagram of the major late transcription unit showing the alternatively 635 
spliced mRNAs and encoded proteins. (B) Organisation of the L4-22K and L4-33K ORF. The 636 
position of the L4-22K truncation mutation in L4-22K- is indicated (31). (C) 293TETOFF cells, 637 
which constitutively express the tetracycline transactivator protein were transfected with pBiL1-638 
3NheI (which expresses the MLTU L1-3 region under the control of a tetracycline-regulated 639 
promoter), pCMV100KFLAG and either empty vector or the L4-22KFLAG or L4-33KFLAG 640 
expression plasmids. Cell lysates were harvested 48h post-transfection, separated on 10% 641 
polyacrylamide gel and late proteins, as indicated on the right, detected by western blot analysis 642 
using AbJLB1 polyclonal anti-late protein serum. The positions to which proteins of known 643 
molecular mass migrated are shown on the left (kDa). 644 
 645 
Figure 2. Late protein expression from L4-22K- genome.  Cells were mock transfected  or 646 
transfected with L4-22K- genome and either empty vector or various L4 expression plasmids as 647 
indicated. Ad5 wt genome was used as a control. Cell lysates were separated on 10% polyacrylamide 648 
gels and expressed proteins, as indicated at the right of each panel, detected by western blot analysis 649 
using either AbJLB1 polyclonal anti-late protein antiserum (top panels, A & B), RI polyclonal anti-650 
late protein antiserum to detect fibre (B) or monospecific / monoclonal antibodies as indicated. In top 651 
panel B, all lanes shown derive from the same exposure of a single blot with irrelevant lanes excised 652 
for clarity of presentation. Note that no FLAG-tagged 22K is detected from transfection of the single 653 
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L4-22/33K plasmid as the tag sequence is only attached to the 33K reading frame. However, the 654 
expected expression of 22K from this plasmid can be inferred from its effect on late protein 655 
expression. The positions to which proteins of known molecular mass migrated are shown on the left 656 
(kDa).  657 
 658 
Figure 3. L4-22K has no effect on viral DNA replication. (A) Confirmation of L4-22K- mutant 659 
status. L4-22K- virus was generated and passaged five times in a stable L4-22K complementing cell 660 
line, 293-L4-22K. Ad5 26018-27086 bp region was amplified by PCR from DNA isolated from 661 
either L4 22K- or wt virus particles. PCR products were either undigested or digested with AvrII as 662 
indicated. Lane M, 1kb ladder, sizes marked on the left (kbp). (B) L4-22K effects on packaging. 293 663 
cells were either mock transfected or transfected with L4-22KFLAG and 24 h. later infected with 2 x 664 
10-3 FFU/cell L4-22K- virus or Ad5 wt. Packaged DNA isolated from infected cells at either 3 h. p.i. 665 
or 20 h. p.i. was digested with HindIII and analysed by southern blotting using an L1 probe. (C) L4-666 
22K effects on replication. As B. except DNA was obtained by HIRT extraction of cell cultures at 3 667 
h. or 20 h. 50ng Ad5wt viral DNA was used as a positive control (B & C). 668 
 669 
Figure 4. Restoring expression levels of the intermediate proteins IVa2 and IX does not fully 670 
complement L4-22K-.  (A&B) 293 cells were mock transfected, or transfected with L4-22K- 671 
genome and either empty vector or various expression plasmids as indicated. (C) 293 cells were 672 
mock transfected, or transfected with the IVa2 expression plasmid with either empty vector or 673 
various L4-protein expression vectors as indicated. Cell lysates were separated on 10% or 15% 674 
polyacrylamide gels and expressed proteins detected by western blot analysis using anti-IVa2, anti-675 
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IX or AbJLB1 anti-late protein antisera. The positions to which proteins of known molecular mass 676 
migrated are shown on the left (kDa). 677 
 678 
Figure 5. L4-22K increases transcription activity of IVa2 at the MLP. (A) 293 cells were 679 
transfected with pMLP+DEluc (black bars) or pMLP-DEluc (grey bars), alone or with L4-22K- 680 
genome and various expression plasmids as indicated. (B) 293 cells (grey bars) or 293-IVa2 (black 681 
bars) cells were transfected with pMLP+DEluc (black bars), alone or with L4-22K- genome and 682 
various expression plasmids as indicated. Firefly luciferase expression was detected using a 683 
luciferase assay, corrected for transfection efficiency using β-galactosidase expression from an 684 
independent control plasmid, and expressed as fold induction where expression from the reporter 685 
plasmids alone was set as 1. Error bars show standard deviations where n = 3. (C) 293 or 293-IVa2 686 
cells were transfected with L4-22K- genome and either empty vector or L4-22KFLAG expression 687 
plasmid. Cell lysates were separated on 10% polyacrylamide gels and expressed proteins detected by 688 
western blot analysis using AbJLB1 anti-late protein or anti-IVa2 antisera. The positions to which 689 
proteins of known molecular mass migrated are shown on the left (kDa). 690 
 691 
Figure 6. L4-22K increases the level of late mRNA. RT-PCR amplifications were performed on 692 
total cytoplasmic RNA from 293 cells that were either mock transfected or transfected with L4-693 
22KFLAG and 24 h. later infected with 2x10-3 FFU/cell L4-22K- virus or Ad5 wt as indicated. Late 694 
mRNAs were detected by RT-PCR using a 5’ primer specific for tripartite leader 1 and 3’ primers 695 
directed to L2 penton (947bp product), L2 V (1138bp) or L3 hexon (662bp) 3’exons. Equivalent 696 
control reactions were performed lacking reverse transcriptase (RT-); amplification of β-actin mRNA 697 
(511bp product) served as a positive control. For V mRNA, both RT-PCR and RT- results derive 698 
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from the same experiment and are presented at the same exposure. The positions to which DNA size 699 
markers migrated are indicated (kbp). 700 
 701 
Figure 7. L4-22K acts at the level of RNA processing. 293 cells were either mock transfected or 702 
transfected with L4-22KFLAG expression vector. 24h post-transfection, cells were mock-infected, or 703 
infected with 2 x 10-3 FFU/cell L4-22K- virus or Ad5 wt and nuclear RNA isolated 20h p.i. Amounts 704 
of L3 RNA unprocessed at the L3 polyA site (upper left panel), and of E2A RNA unprocessed at its 705 
polyA site (upper right panel), were determined by RT-PCR using specific primers. β-actin mRNA 706 
served as a positive control (lower left panel).  To confirm that amplified products derived from 707 
RNA template, the same amount of RNA was added to reactions where the reverse transcriptase had 708 
been omitted (lower right panel). The positions to which DNA size markers migrated are indicated 709 
(kbp).  710 
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